Literature DB >> 2494241

Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.

J O Parker1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494241     DOI: 10.1016/0735-1097(89)90217-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

1.  Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.

Authors:  J A Bauer; J P Balthasar; H L Fung
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

Review 2.  Transdermal nitroglycerin. Does it really work in the treatment of angina?

Authors:  A Fletcher
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

3.  Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance.

Authors:  T Münzel; A Giaid; S Kurz; D J Stewart; D G Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

4.  Suppression of PKG by PDGF or nitric oxide in differentiated aortic smooth muscle cells: obligatory role of protein tyrosine phosphatase 1B.

Authors:  Daming Zhuang; Poonam Balani; Qinghua Pu; Shalini Thakran; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

5.  Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin.

Authors:  G Abou-Mohamed; W H Kaesemeyer; R B Caldwell; R W Caldwell
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP.

Authors:  G A Soff; T L Cornwell; D L Cundiff; S Gately; T M Lincoln
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.